Oculis Holding AG (NASDAQ:OCS) Stock Has Average Price Target of $39.44 According to Brokerages

Key Points

• Analyst sentiment is moderately bullish: Ten brokerages rate Oculis a “Moderate Buy,” with nine buys and one sell. The average 12-month price target is $39.44, well above the stock’s recent price of $7.88.
• Oculis shares have declined sharply: The stock is near its 12-month low of $7.85, compared with a high of $34.47, and trades below both its 50-day and 200-day moving averages.
• Institutional ownership and business risks remain notable: Institutional investors own 22.3% of the company, while Oculis continues to report losses and analysts forecast a full-year loss of $2.01 per share. The biopharmaceutical company is developing ophthalmic treatments including OCS-01 and licaminlimab.

Oculis Holding AG (NASDAQ:OCS - Get Free Report) has earned an average rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $39.44.

Several equities research analysts recently commented on OCS shares. Wall Street Zen raised Oculis from a "strong sell" rating to a "sell" rating in a report on Saturday, August 8th. JPMorgan Chase & Co. lowered their price objective on Oculis from $23.00 to $20.00 and set an "overweight" rating on the stock in a research note on Friday, August 14th. Weiss Ratings restated a "sell (d-)" rating on shares of Oculis in a report on Friday, July 17th. Finally, HC Wainwright upped their target price on Oculis from $26.00 to $39.00 and gave the company a "buy" rating in a report on Friday, September 18th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC grew its holdings in shares of Oculis by 326.4% in the second quarter. Squarepoint Ops LLC now owns 61,605 shares of the company's stock valued at $854,000 after purchasing an additional 47,158 shares during the period. Braidwell LP purchased a new position in Oculis during the second quarter worth about $11,570,000. Bank of America Corp DE raised its stake in Oculis by 9.1% during the first quarter. Bank of America Corp DE now owns 69,764 shares of the company's stock worth $1,855,000 after purchasing an additional 5,813 shares during the period. Himension Capital Singapore PTE. LTD. acquired a new position in Oculis in the 1st quarter valued at about $503,000. Finally, Koshinski Asset Management Inc. acquired a new position in Oculis in the 1st quarter valued at about $238,000. Institutional investors and hedge funds own 22.30% of the company's stock.

Oculis Stock Down 5.5%

OCS stock opened at $7.88 on Tuesday. The company has a current ratio of 8.35, a quick ratio of 8.35 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average of $11.15 and a two-hundred day moving average of $16.91. Oculis has a 12 month low of $7.85 and a 12 month high of $34.47. The company has a market cap of $456.91 million, a price-to-earnings ratio of -4.53 and a beta of 0.62.

Oculis (NASDAQ:OCS - Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. The company had revenue of $0.38 million for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%. As a group, analysts forecast that Oculis will post -2.01 earnings per share for the current fiscal year.

About Oculis

Oculis NASDAQ: OCS is a biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company aims to address significant unmet needs in ophthalmology through therapies designed for topical, noninvasive administration and other targeted delivery approaches.

Oculis' pipeline has included OCS-01, a topical dexamethasone formulation being developed for retinal diseases such as diabetic macular edema, and licaminlimab (OCS-02), an ophthalmic anti-TNF biologic being investigated for conditions including dry eye disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.